ICAM1 and Cowden disease: IFN beta-1a is an approved treatment for MS53 and has been investigated as a potential treatment for CD as well, due to its ability to down-regulate the expression of interleukin-12, a cytokine that is thought to be involved in mucosal degeneration in CD54.